Skip to main content

Table 3 Mean results, incremental effects, costs, cost-effectiveness ratio and Incremental Cost-Effectiveness Ratio (ICER)

From: Scenario drafting to anticipate future developments in technology assessment

Model scenario time Mean value parameter Δeffects* Δcosts* ICER
   failure NC uptake    
Start 2005 0.27 0.35 0.03 0.0010 € 1,940 € 1,9 mill
Separate scenarios
Failure 2010 0.20 Idem Idem 0.0011 € 2,094 € 1,9 mill
2020 0.08 Idem Idem 0.0013 € 2,385 € 1,9 mill
Non-compliance 2010 Idem 0.26 Idem 0.0011 € 1,939 € 1,7 mill
2020 Idem 0.08 Idem 0.0013 € 1,940 € 1,5 mill
Uptake 2010 Idem Idem 0.50 0.0592 € 1,547 € 26,145
2020 Idem Idem 0.92 0.1089 € 1,211 € 11,123
Combined scenarios
2005 0.27 0.35 0.03 0.0010 € 1,940 € 1,9 mill
2010 0.20 0.26 0.50 0.0728 € 1,630 € 22,388
2020 0.08 0.08 0.92 0.1492 € 1,171 € 7,853
  1. Δeffects: Incremental effects of 70-gene signature compared to the Adjuvant Online, Δcosts: Incremental costs of 70-gene signature compared to the Adjuvant Online, ICER: Incremental cost-effectiveness ratio, NC: non compliance.